Phase 4 N=41 Suvorexant and Trauma Related Insomnia
Insomnia · Posttraumatic Stress Disorder
Primary: Change in Insomnia Severity Index Score From Baseline. — 6.8; 8.6 units on a scale — p=<.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=279 Dismantling the Components and Dosing of CBT for Co-Occurring Disorders
CBT Decoupling · CBT Anxiety Reduction · CBT Combined
Primary: Number of Participants That Relapsed to Drinking at 4 Months — 30; 43; 35 Participants — p=.673
N/A N=164 To Evaluate the Safety and Efficacy of the Saline-coupled Bipolar Sealer in Primary Unilateral Total Knee Arthroplasty
Surgical Blood Loss
Primary: Hemostasis — 924; 1062 milliliters — p=0.1254
Phase 3 N=511 Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis
Postmenopausal Osteoporosis
Primary: Percent Change From Baseline in Lumbar Spine BMD at Month 12 — 10.8571; 7.1361 percent change
N/A N=201 Evaluation of the Effectiveness and Safety of the Ulthera® DeepSEE® System for Treating Skin Laxity in the Lower Face and Submentum
Improvement in Skin Laxity of the Lower Face and Submentum
Primary: Percentage of Subjects With Improvement in Lower Face and Submental Skin Laxity at Day 90 — 54.2; 47.0 percentage of subjects
N/A N=297 Evaluation of the INDICAID™ COVID-19 Rapid Antigen Test
Covid19
Primary: Test Concordance — 85.3 positive percent agreement
N/A N=9 Ocular Sarcoidosis Open Label Trial of ACTHAR Gel
Ocular Sarcoidosis · Panuveitis · Anterior Uveitis
Primary: Percentage of Patients With Clinically Significant Improvement in Visual Acuity — 3 Participants
N/A N=24 A Prospective Case Series Evaluating Surgimend Mp® In Patients Undergoing Complex Abdominal Hernia Repair
Hernia, Ventral
Primary: The Frequency of Hernia Recurrence Diagnosed by Physical Exam or CT Scan (if Clinically Indicated) — 1 Participants
Phase 3 N=362 Phase III Study of CG100649 in Osteoarthritis Patients
Localized Primary Osteoarthritis of Hip · Localized Primary Osteoarthritis of Knee
Primary: Change in WOMAC-Pain Subscale — 26.8; 27.9; 27.7; 24.2 units on a scale — p=0.011
Phase 2 N=368 University of Utah COVID-19 Hydrochloroquine Trial
Coronavirus Infection · Coronavirus · Infectious Disease
Primary: Duration of Viral Shedding — 9.532447; 10.39556 Days
Phase 2 N=78 A Study to Evaluate the Safety and Efficacy of VIB4920 in Participants With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Change From Baseline to Day 113 in DAS28-CRP — -1.06; -1.90; -1.87; -1.87 score on a scale — p=0.0296
Phase 1 N=50 A Study of Ramucirumab (LY3009806) in Healthy Participants
Healthy
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 1; 0 Participants
N/A N=287 Comparative Study of the ANNE™ One System to Diagnose Obstructive Sleep Apnea
Obstructive Sleep Apnea of Adult
Primary: Sensitivity and Specificity of Obstructive Sleep Apnea (OSA) Diagnosis Using ANNE Sleep System Compared to Polysomnography — 89.7; 97.5 percentage of true cases
Phase 3 N=778 Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine
Chronic Migraine
Primary: Change From Baseline in Mean Monthly Migraine Days Across 12-Week Treatment Period in mITT Population — -4.63; -7.13; -7.27 migraine days per month — p=0.0001
N/A N=615 Hepatocellular Carcinoma Surveillance in Cirrhotics
Hepatocellular Carcinoma · Cirrhosis
Primary: HCC Screening Completion — 27.6; 54.5; 54.1 Percentage of participants